Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection

Atsushi Saito, Yuei Irabu, Hiroshi Fukuhara, Masakichi Motomiya, Akira Watanabe, Kotaro Oizumi, Hiroyuki Kobayashi, Hiroshi Oshitani, Koichiro Nakata, Yoshitaka Nakamori, Tatsuo Nakatani, Naohiko Chonabayashi, Fumio Matsumoto, Takeo Imai, Toshiyuki Yamamoto, Kanzo Suzuki, Kazuhide Yamamoto, Rinzo Soejima, Niro Okimoto, Yoshihisa NakagawaMasaru Sumi, Masaru Nasu, Hideaki Shigeno, Jun Goto, Hiroyuki Nagai, Toru Yamasaki, Kohei Hara, Yasumasa Doutsu, Naofumi Suyama, Hiroshi Tomita, Osamu Sakito, Keizo Matsumoto, Hirofumi Tanaka, Nobuya Ogawa, Keizo Yamaguchi, Keizo Yamaguchi

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    A comparative clinical study on levofloxacin (LVFX, DR-3355) was conducted to determine the optimal dose of LVFX for treatment of chronic respiratory tract infections. Ofloxacin (OFLX) was used as the active control. LVFX at doses of 600 mg (200 mg t.i.d., LV600), and 300 mg (100 mg t.i.d., LV300) and OFLX at a dose of 600 mg (200 mg t.i.d., OF600) were allocated by the envelope randomization method and administered for 14 days as a rule. 1) The clinical efficacy rates, judged by the committee, were 71.4% (20/28) for the LV600 group, 76.0% (19/25) for the LV300 group and 82.6% (19/23) for the OF600 group. No significant differences were found among the three groups. 2) The elimination rates, based on the bacteriological efficacy, were 73.7% (14/19) in the LV600 group, 72.2% (13/18) in the LV300 group and 76.9% (10/13) in the OF600 group. No significant differences were found among three groups. 3) The incidences of side effects were 10.7% (3/28) in the LV600 group, 3.8% (1/26) in the LV300 group and 7.7% (2/26) in the OF600 group. The incidences of abnormal changes in the laboratory findings were 14.8% (4/27) in the LV600 group, 0% (0/25) in the LV300 group and 13.0% (3/23) in the OF600 group. No significant differences were found among the three groups. 4) The utility rates, judged by the committee, were 60.0% (15/25) for the LV600 group, 73.9% (17/23) for the LV300 group and 71.4% (15/21) for the OF600 group. When judged by the doctors in charge, the rates were 76.0% (19/25) for the LV600 group, 72.7% (16/22) for the LV300 group and 57.1% (12/21) for the OF600 group. No significant differences were found among the three groups. Based on these results, we surmise that a dose of 100 mg t.i.d. is the optimal dose of LVFX for the treatment of respiratory tract infections.

    Original languageEnglish
    Pages (from-to)75-96
    Number of pages22
    JournalChemotherapy
    Volume40
    DOIs
    Publication statusPublished - 1992 May

    Keywords

    • DR-3355
    • LVFX
    • Levofloxacin

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint

    Dive into the research topics of 'Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection'. Together they form a unique fingerprint.

    Cite this